New molecular targets and proof-of-concept therapies for Autism Spectrum Disorders

Información del proyecto

THERAUTISM

Identificador del acuerdo de subvención: 851231

DOI

10.3030/851231

Proyecto cerrado

Fecha de la firma de la CE 7 Octubre 2019

Fecha de inicio 1 Marzo 2020

Fecha de finalización 31 Agosto 2025

Financiado con arreglo a

• EXCELLENT SCIENCE - European Research Council (ERC)

Coste total

€ 1 499 025,00

Aportación de la UE

€ 1 499 025,00

Coordinado por

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France

Periodic Reporting for period 4 - THERAUTISM (New molecular targets and proof-of-concept therapies for Autism Spectrum Disorders)

Período documentado: 2024-09-01 hasta 2025-08-31

Resumen del contexto y de los objetivos generales del proyecto

Autism spectrum disorder (ASD) is a complex, polygenic neurodevelopmental and lifelong condition. It is characterized by impairments in social communication and interaction, as well as repetitive and stereotyped behaviors. The prevalence of ASD has increased, now affecting 1% of children worldwide. The major gap in ASD remains the absence of effective drugs for managing core features of ASD. Behavioral interventions have shown some efficacy in addressing social impairments, but they are costly (€258 billion/year), highly intensive (35h/week) and effective when applied in young children with ASD. Despite extensive efforts, no drug capable of benefiting larger numbers of individuals independently of their age has been approved for core symptoms of ASD. Currently, only the antipsychotics risperidone and aripiprazole are approved to treat co-occurring features. This highlights the urgent need to develop effective drugs that directly target the core features of the condition. To achieve this goal, it requires the identification of new and promising therapeutic targets.
The EU-funded THERAUTISM project aimed to overcome this research gap, from the identification of new molecular targets to the initial step of therapeutic development. Its first objective was to identify all the molecular substrates within a small, highly conserved brain circuit implicated in social interaction deficits. The second objective of the project was to investigate two of these substrates—after characterizing the function of a newly discovered protein—with the aim of improving social deficits in several preclinical mouse models of ASD.
Overall, the THERAUTISM project aimed to identify novel therapeutic targets and innovative therapies for ASD. The project was divided into two parts:
1) identification of new molecular targets involved in social interaction deficits.
2) investigation of two specific substrates to determine the most effective therapeutic approaches to restore their function.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Since the launch of the project in March 2020, we have successfully identified the most suitable and robust preclinical mouse models of ASD, implemented all required techniques, and set up the experimental conditions in the laboratory.
Part 1 focused on identifying novel molecular substrates within a conserved brain circuit linked to social interaction deficits. We generated a substantial database containing 560 samples, enabling comprehensive mapping of these substrates. Through this effort, we already identified promising and highly druggable targets, including some unexpected ones within this neuronal circuit.
Part 2 aimed to investigate two specific substrates of social interactions. Our studies revealed that only one of these two targets was differentially dysregulated, but only in a subset of preclinical models of ASD (1 published article). In contrast, the second target was not specifically involved in social interaction deficits (1 published article, 1 under revision). Importantly, we identified a selective pharmacological compound capable of improving social interaction, which could represent a new strategic therapeutic option for individuals with ASD.
The THERAUTISM project resulted in 2 published research articles, 2 published reviews, 3 currently under revision, 1 database and 4 research articles in preparation, and the work was presented in 8 national and 8 international meetings.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The identification of new therapeutical targets and the development of treatments to improve the core social features of ASD have long remained major research gaps. The THERAUTISM project addressed these gaps, by providing a substantial database of molecular substrates underlying social interaction deficits and by advancing new pharmacological compounds for ASD. As a result, the project provides valuable resources for the scientific community and paves the way for the development of innovative therapeutic options. Ultimately, the outcomes of the THERAUTISM project offer new therapeutical options for individuals with ASD.

outline of the project